Aniracetam (powder) – 50g

Aniracetam — 50 g (powder, glass jar)

1-(4-Methoxybenzoyl)pyrrolidin-2-one (Aniracetam) — a pyrrolidinone racetam used widely as a reference positive allosteric modulator (PAM) for AMPA-type ionotropic glutamate receptors in in-vitro electrophysiology and receptor-kinetics research. Supplied by Peptide Tech at ≥ 99% purity (HPLC/MS verified) for in-vitro, cellular, and biochemical research use only (RUO). Not for human or veterinary use.

 

Specifications

CAS Number	72432-10-1
Chemical Name	1-(4-Methoxybenzoyl)pyrrolidin-2-one (Aniracetam)
PubChem CID	2196
Molecular Formula	C12H13NO3
Molecular Weight	219.24 g/mol
Sequence	N/A (small-molecule; not a peptide)
Physical Appearance	White to off-white crystalline powder
Container	Type I amber glass jar (net content: 50 g)
Purity	≥ 99% (verified by HPLC & MS; third-party tested)
Solubility	Water: insoluble. DMSO: up to ~44 mg/mL. Ethanol: ~11–18 mg/mL. Prepare concentrated DMSO or ethanol stocks, then dilute into final assay buffer with mixing; filter (0.22 µm) if needed for clarity.

Molecular Structure (Reference)

Why Peptide Tech

• Same-Day Shipping
• GMP-Aligned Lyophilized Peptides
• USA Made
• 24/7 Support
• Price Match Guarantee
• Batch Tracking with QR Code Verification
• 3rd-Party USA Lab Testing — purity, quantity, endotoxin
• Cold-Chain Shipping — Always (no paid upgrade)
• Worldwide Shipping
• All Major Payments Accepted
• Text & Email Order Updates
• 2-Day FedEx/UPS Shipping Standard
• Cheapest Overnight Rates
• Largest Variety of Peptides & Bioregulators

Storage & Handling

• Solid (unopened): Store sealed at 2–8 °C, protected from light and moisture. For long-term archival, ≤ −20 °C is recommended.
• Solutions: Aliquot DMSO/EtOH stocks into low-binding tubes; store at ≤ −20 °C. Avoid repeated freeze–thaw cycles.
• Handling: Allow container to equilibrate to room temperature before opening to minimize condensation. Reseal promptly; consider inert-gas backfill if frequently accessed.
• Research Use Only (RUO): Not for human or veterinary use, ingestion, diagnostic, or therapeutic applications.

 

Potential Applications in Research

Strictly in-vitro, cellular, or biochemical contexts — no clinical or human-use claims.

• AMPA receptor pharmacology: quantify PAM-dependent effects on deactivation and desensitization by whole-cell or outside-out patch clamp.
• Receptor isoform studies: compare flip/flop splice variants and site-directed mutants for sensitivity to racetam-class modulators.
• Synaptic physiology: examine effects on fast excitatory postsynaptic current (EPSC) decay and short-term plasticity in neurons or brain slices.
• Ligand benchmarking: use as a reference modulator alongside cyclothiazide, CX-series, and other AMPAR PAMs.
• Structure–activity relationship (SAR): evaluate racetam/ampakine analog panels against AMPAR gating kinetics.
• Computational docking/modeling of AMPAR ligand-binding domain (LBD) interfaces with PAMs.

 

Citations (PubMed)

• Isaacson, J. S., & Nicoll, R. A. “Aniracetam reduces glutamate receptor desensitization and slows the decay of fast excitatory synaptic currents in the hippocampus.” Proc Natl Acad Sci USA, 1991. PubMed
• Partin, K. M., Fleck, M. W., & Mayer, M. L. “AMPA receptor flip/flop mutants affecting deactivation, desensitization, and modulation by cyclothiazide, aniracetam, and thiocyanate.” J Neurosci, 1996. PubMed
• Lawrence, J. J., Brenowitz, S., & Trussell, L. O. “The mechanism of action of aniracetam at synaptic AMPA receptors: indirect and direct effects on desensitization.” Mol Pharmacol, 2003. PubMed
• Jin, R., et al. “Mechanism of positive allosteric modulators acting on AMPA receptors.” Proc Natl Acad Sci USA, 2005. PMC

 

Compliance & RUO Disclaimer

For laboratory research use only (RUO). Not a drug, food, or cosmetic. Not for human or veterinary use. Purchase and use are limited to qualified personnel operating under institutional laboratory guidelines.